Starling Oncology
STLN
47 hedge funds and large institutions have $28.2M invested in Starling Oncology in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
4% more funds holding
Funds holding: 45 → 47 (+2)
1.61% less ownership
Funds ownership: 25.01% → 23.4% (-1.6%)
26% less capital invested
Capital invested by funds: $38.2M → $28.2M (-$10M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$898K |
| 2 |
FCM
FourWorld Capital Management
New York
|
+$476K |
| 3 |
FL
FreeGulliver LLC
New Orleans,
Louisiana
|
+$234K |
| 4 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$193K |
| 5 |
QFA
Quattro Financial Advisors
The Woodlands,
Texas
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAIC
Josh Arnold Investment Consultant
Edina,
Minnesota
|
-$3.79M |
| 2 |
EPA
Element Pointe Advisors
Miami,
Florida
|
-$378K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$216K |
| 4 |
BlackRock
New York
|
-$168K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$80.1K |
STLN Hedge Fund Activity: Q1 2024 in Review
47 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q1 2024, worth a combined $28.2M — down 26% from $38.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new STLN positions and 5 closed out — a net gain of 2 holders — while 14 added to existing stakes and 12 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $898K. The largest seller was Josh Arnold Investment Consultant, exiting entirely with an estimated $3.79M sold.
- 47 institutional investors held Starling Oncology (STLN) as of Q1 2024, up from 45 in Q4 2023.
- Funds reported $28.2M of Starling Oncology stock for Q1 2024, down 26% quarter-over-quarter.
- 7 funds opened new Starling Oncology positions in Q1 2024 and 5 closed out, a net change of +2 holders.
- The largest Starling Oncology buyer in Q1 2024 was Balyasny Asset Management, an estimated $898K added.
- The largest Starling Oncology seller in Q1 2024 was Josh Arnold Investment Consultant, an estimated $3.79M sold.
Based on aggregated 13F filings for Q1 2024.